Vertommen et al., 1994 - Google Patents
Flavonoid treatment reduces glycation and lipid peroxidation in experimental diabetic ratsVertommen et al., 1994
- Document ID
- 2446433850094355731
- Author
- Vertommen J
- Van den Enden M
- Simoens L
- De Leeuw I
- Publication year
- Publication venue
- Phytotherapy Research
External Links
Snippet
It has been reported that flavonoids in vitro have the capacity to inhibit aldose reductase. The aim of this study was to evaluate this property in vivo. We chose diosmin, a freely available and inexpensive flavonoid without major side effects. Streptozotocin diabetic rats …
- 206010012601 Diabetes mellitus 0 title abstract description 36
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K8/00—Cosmetic or similar toilet preparations
- A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beyer-Mears et al. | Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil | |
| Arican et al. | Oxidative stress in the blood of patients with active localized vitiligo | |
| Coppey et al. | Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve | |
| Panjamurthy et al. | Lipid peroxidation and antioxidant status in patients with periodontitis | |
| Muriach et al. | Lutein effect on retina and hippocampus of diabetic mice | |
| Vertommen et al. | Flavonoid treatment reduces glycation and lipid peroxidation in experimental diabetic rats | |
| Roig et al. | Moderate red wine consumption protects the rat against oxidation in vivo | |
| Kowluru et al. | Abnormalities of retinal metabolism in diabetes or experimental galactosemia. VI. Comparison of retinal and cerebral cortex metabolism, and effects of antioxidant therapy | |
| Cadenas et al. | Endotoxin increases oxidative injury to proteins in guinea pig liver: protection by dietary vitamin C | |
| Al Shamsi et al. | Beneficial effect of vitamin E on the metabolic parameters of diabetic rats | |
| Gonzalez et al. | Antioxidant systemic effect of short-term Cerebrolysin® administration | |
| Robinson et al. | Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. | |
| Ataizi et al. | Evaluation of the neuroprotective role of boric acid in preventing traumatic brain injury-mediated oxidative stress | |
| Adegbesan et al. | ORAL CELLGEVITY® improves antioxidant parameters and stalls damages in STZ-diabetic rat pancreas | |
| Obasi et al. | GC-MS analysis, pH and antioxidant effect of Ruzu herbal bitters on alloxan-induced diabetic rats | |
| Arokoyo et al. | Antioxidant activities of Basella alba aqueous leave extract in blood, pancreas, and gonadal tissues of diabetic male Wistar rats | |
| Eze et al. | Effects of Lycopene on Liver Markers and Glucokinase Activity in Experimentally-induced Diabetes Mellitus Rat Model. | |
| Amudha et al. | Toxicological, biochemical and histopathological evaluation of the ethanolic extract of seagrass-Enhalus acoroides in albino wistar rats | |
| Mitton et al. | Modelling cortical cataractogenesis 21: in diabetic rat lenses taurine supplementation partially reduces damage resulting from osmotic compensation leading to osmolyte loss and antioxidant depletion | |
| Zimitat et al. | Progression of neurological disease in thiamin-deficient rats is enhanced by ethanol | |
| Altan et al. | Effect of the sulfonylurea glyburide on superoxide dismutase activity in alloxan-induced diabetic rat hepatocytes | |
| Van Dam et al. | Effects of insulin treatment on endoneurial and systemic oxidative stress in relation to nerve conduction in streptozotocin‐diabetic rats | |
| Kamuren et al. | Effects of low-carbohydrate diet and Pycnogenol® treatment on retinal antioxidant enzymes in normal and diabetic rats | |
| Dallatu et al. | Antioxidant micronutrient potentials in strengthening the antioxidant defense in alloxan-induced diabetic rats | |
| King et al. | Rate of excretion of vitamin C in human urine |